There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa .
CONCLUSION BoNT-A is effective and safe in treating NDO after SCI .
There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa .
PURPOSE OnabotulinumtoxinA ( BoNT-A ) is a promising therapy for treating neurogenic detrusor overactivity ( NDO ) in individuals with spinal cord injury ( SCI ) .
This systematic review and meta- analysis aim ed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI .
Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
OBJECTIVE To evaluate the impact of botulinum toxin type A ( BoNTA ) on health-related quality of life in patients with neurogenic urinary incontinence ( UI ) using the Incontinence Quality of Life question naire ( I-QOL ) . METHODS R and omized , double-blind , multicenter , placebo-controlled study involving eight centers across Belgium , France , and Switzerl and . Patients ( n = 59 ) with UI due to neurogenic detrusor overactivity ( spinal cord injury , n = 53 ; multiple sclerosis , n = 6 ) who were inadequately managed on oral anticholinergics  received a single dose of BoNTA ( 200U or 300U , Botox ) or placebo .  I-QOL scores at screening and after treatment at weeks 2 , 6 , 12 , 18 , and 24 were recorded . RESULTS Median total and subscale I-QOL scores increased significantly from screening with BoNTA 300U compared with placebo at all time points ( p<0.05 ) and with BoNTA 200U compared with placebo at all time points for total score and the Avoidance Limiting Behavior subscale ( p<0.05 ) , and at weeks 2 , 6 , 12 , and 18 ( p<0.05 ) , but not 24 for the Psychosocial Impact and Social Embarrassment subscales . Approximately twice as many BoNTA recipients as placebo recipients achieved at least a minimal important difference in total I-QOL score at 2 , 6 , 12 , and 24 wk . CONCLUSIONS BoNTA significantly improves UI-associated health-related quality of life in patients with neurogenic UI
There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa .
CONCLUSION BoNT-A is effective and safe in treating NDO after SCI .
There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa .
PURPOSE OnabotulinumtoxinA ( BoNT-A ) is a promising therapy for treating neurogenic detrusor overactivity ( NDO ) in individuals with spinal cord injury ( SCI ) .
This systematic review and meta- analysis aim ed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI .